COMPANY

TORL BioTherapeutics

HQ: Culver City, CA source · torlbio.com ↗

Profile checked Oct 10, 2026

Keywords: Fallopian Tube Cancers Gastric Cancer Pancreas Cancer Gastroesophageal Junction Adenocarcinoma Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Hepatocellular Carcinoma FIGO Stage III and IV Ovarian Cancer Primary Peritoneal Cancer Ovarian Cancer Endometrial Cancer NSCLC Epithelial Ovarian Cancer Primary Peritoneal Endometrioid Ovarian Cancer Colorectal Cancer TORL-4-500 TORL-1-23 TORL-2-307-ADC TORL-3-600 TORL-2-307-MAB

8Trials (company is sponsor)

Timeline

Mar 31, 2026 Trial start Phase 1/Phase 2: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma source ↗
Dec 10, 2025 Trial start Phase 1/Phase 2: CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer source ↗
Nov 20, 2024 Trial start Phase 2: CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. source ↗
Dec 4, 2023 Trial start 1: A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer source ↗
Sep 29, 2023 Trial start Phase 1: First in Human Study of TORL-3-600 in Participants With Advanced Cancer source ↗
Feb 2, 2022 Trial start Phase 1: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer source ↗
Jan 20, 2022 Trial start Phase 1: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer source ↗
Nov 17, 2021 Trial start Phase 1: First in Human Study of TORL-1-23 in Participants With Advanced Cancer source ↗

Upcoming milestones

Mar 29, 2027 (ESTIMATED) · 1 · A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer · NCT06005740
2027-10 (ESTIMATED) · Phase 2 · CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. · NCT06690775
2027-12 (ESTIMATED) · Phase 1/Phase 2 · CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer · NCT07322094
Mar 31, 2029 (ESTIMATED) · Phase 1/Phase 2 · A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma · NCT07439653

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT07439653	A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma	Phase 1/Phase 2	Recruiting	Mar 31, 2026	Mar 31, 2029 (estimated)
NCT06005740	A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer	1	Active, not recruiting	Dec 4, 2023	Mar 29, 2027 (estimated)
NCT07322094	CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer	Phase 1/Phase 2	Recruiting	Dec 10, 2025	2027-12 (estimated)
NCT05103683	First in Human Study of TORL-1-23 in Participants With Advanced Cancer	Phase 1	Recruiting	Nov 17, 2021	Aug 31, 2026 (estimated)
NCT05156866	First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer	Phase 1	Active, not recruiting	Feb 2, 2022	Jun 15, 2026 (estimated)
NCT06690775	CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.	Phase 2	Recruiting	Nov 20, 2024	2027-10 (estimated)
NCT05948826	First in Human Study of TORL-3-600 in Participants With Advanced Cancer	Phase 1	Active, not recruiting	Sep 29, 2023	Jun 25, 2026 (estimated)
NCT05159440	First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer	Phase 1	Active, not recruiting	Jan 20, 2022	Dec 15, 2024 (estimated)